BillionToOne, Inc. (BLLN) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection.
Is BillionToOne, Inc. stock overvalued or undervalued in 2026?
As of October 5, 2026, BillionToOne, Inc. (BLLN) trades at 171× earnings (P/E), against a median of 27.5× across the 157 pharma companies above $2bn in Kaplio's universe. Kaplio's verdict: expensive. At its sector median (27.5×) $17 (-84 %).
Kaplio overview: BillionToOne, Inc.
Market cap $5B · 52 weeks $64 – $150 (27 % below the high) · P/E 171× · 2027 expected P/E 103× · Dividend none · Next earnings October 6, 2026 · expected EPS $0.16 · Price as of Oct 5 · accounts published Aug 5.
- Valuation: P/E 170.8× (expensive).
- Business: ROIC 6 % (weak).
- Balance sheet: Net debt/EBITDA −19.6× (solid).
- Earnings: 2 of 5 (disappointing).
What would it be worth at its usual multiples?
At its sector median (27.5×) $17 (-84 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 3 of 5 pass
- ROIC 6.3 %, fails.
- Gross margin 68.3 %, borderline.
- R&D / Revenue 16.2 %, passes, near the threshold.
- FCF / Net Income 210.8 %, passes.
- Net debt / EBITDA −19.6×, passes.
Against its peers (same industry, similar size) — BillionToOne, Inc.: P/E 171×; EV/EBITDA 88.9×; ROIC 6.3 %; $4.9B. Sotera Health Company (P/E 32.4×; EV/EBITDA 13.3×; ROIC 8.8 %; $5.3B), RadNet, Inc. (P/E —; EV/EBITDA 20.8×; ROIC 1.4 %; $5.5B), Veracyte, Inc. (P/E 32.7×; EV/EBITDA 26.2×; ROIC 6.7 %; $3.7B).
Profitability
| Return on Equity | 7.87% |
| Return on Invested Capital | 6.33% |
| Return on Assets | 4.59% |
| Gross Margin | 71.27% |
| Operating Margin | 10.90% |
| Net Margin | 8.43% |
Financial Health
| Debt / Equity | 0.27 |
| Current Ratio | 11.69 |
Price Performance
| 1 month | +9.73% |
| 3 months | -9.57% |
| Year-to-date | +33.26% |
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BLLN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks